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ABSTRACT
Introduction Sarcopenia is a progressive muscle disorder 
characterised by decline in skeletal muscle mass, strength 
and function leading to adverse health outcomes, including 
falls, frailty, poor quality of life and death. It occurs more 
commonly in older people and can be accelerated by 
poor diet and low physical activity. Intervention studies 
incorporating higher dietary protein intakes or protein 
supplementation combined with resistance exercise 
(RE) have been shown to limit muscle function decline. 
However, less is known about the role of whole foods in 
reducing the risk of sarcopenia. Milk is a source of high-
quality nutrients, which may be beneficial for skeletal 
muscle. This pilot study examines the feasibility and 
acceptability of milk consumption with RE to improve 
muscle function in community-dwelling older adults at risk 
of sarcopenia.
Methods and analysis 30 older adults aged ≥65 
years will be randomly allocated to three groups: ‘whole 
milk+RE’, ‘skimmed milk+RE’ or ‘control drink+RE’. 
Assessments will take place in participants’ homes, 
including screening (milk allergies, grip strength, walking 
speed), baseline and postintervention health and function. 
All participants will undertake a structured RE intervention 
twice a week for 6 weeks at a local gym, followed by 
the consumption of 500 mL of whole or skimmed milk 
(each ~20 g of protein) or an isocaloric control drink and 
another 500 mL at home. Participants’ views about the 
study will be assessed using standardised open-ended 
questions. The primary outcomes include feasibility and 
acceptability of the intervention with recruitment, retention 
and intervention response rates. Analyses will include 
descriptive statistics, exploration of qualitative themes and 
intervention fidelity.
Ethics and dissemination Outputs include pilot data 
to support funding applications; public involvement 
events; presentation at conferences and peer-reviewed 
publication.
Trial registration number ISRCTN13398279; Pre-results.
InTRoduCTIon
The UK population is ageing rapidly; the 
number of adults aged ≥65 increased by 17.3% 
in the last decade, and in mid-2017 was esti-
mated to account for 18.2% of the total popu-
lation of 66 million1. Understanding factors 
associated with healthy ageing2 such as diet 
and physical activity3 for optimising health and 
well-being of an ageing population is essential 
for the development of effective interventions.
Sarcopenia is a progressive, generalised 
muscle disorder characterised by decline 
in skeletal muscle mass, strength and func-
tion,4 which leads to an increased risk of falls, 
frailty, disability, low health-related quality 
of life (QoL) and death.5–8 It occurs more 
commonly in older people and can be accel-
erated by poor diet and low physical activity.8 9 
The prevalence of sarcopenia increases with 
advancing age—and although dependent on 
the algorithm used to define sarcopenia10—it 
Strengths and limitations of this study
 ► To our knowledge, this is the first pilot study exam-
ining the feasibility and acceptability of whole versus 
skimmed milk with resistance exercise (RE) inter-
vention in community-dwelling older adults living in 
the UK.
 ► The intervention is conducted in a local gym that 
is easily accessible to older adults who will ben-
efit from the familiarisation with RE programme 
conducted in the community to foster continuous 
engagement.
 ► Postintervention interview will allow for the collec-
tion of qualitative evidence to support planned future 
trial, including better understanding of the barriers 
and facilitators of community-based intervention.
 ► Because this an evaluation of a pilot implementation, 
the sample size is not based on statistical power.
 ► Although we do not anticipate any definite results in 
exploring differences between intervention groups, 
the results will be used to aid power calculations for 
planned future substantive research.
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reaches >20% in men and women aged ≥85 years,11 
resulting in estimated healthcare costs in excess of £2.5 
billion/year in the UK.12 This emphasises the need for 
sustainable preventive measures aimed to preserve and 
optimise muscle health and function in a rapidly ageing 
population before the onset of difficulties leading to or 
exacerbating the risk of sarcopenia.
Protein intake and exercise for healthy muscle ageing
Loss of muscle mass and strength can be accelerated 
by poor diet, low levels of physical activity and the pres-
ence of long-term conditions,8 9 13 leading to diminished 
QoL.7 14 Adequate intake of dietary protein and resis-
tance exercise (RE) are recognised as effective interven-
tions to promote skeletal muscle health and reduction 
of physical decline.15 16 Specifically, intervention studies 
that examined a combined effect of protein supplements, 
comprising essential amino acids (EAA) and RE to stim-
ulate muscle protein synthesis (MPS) have observed 
an increase in total muscle protein within 3–5 hours 
following exercise in both young and older adults.17 
Compared with young adults, older adults experience 
a blunted response after protein ingestion to stimulate 
MPS (anabolic resistance), especially in response to lower 
amounts of protein or EAA of <20 or <10 g, respectively. 
Other studies have shown that greater amounts of protein 
supplementation and intermittent feeding in combi-
nation with repeated bouts of RE resulted in increased 
muscle mass in older adults, even in those diagnosed with 
frailty and sarcopenia.18–20
However, there is limited research on the role of whole 
foods rich in protein (eg, milk and dairy products, fish 
and meats) in maintaining skeletal muscle mass, strength 
and function in older adults at risk of sarcopenia. Regular 
consumption of high-quality, nutrient-dense foods, 
high in macronutrients and micronutrients relevant for 
muscle21 within a varied diet may provide a platform for 
developing strategies for maintenance of muscle health 
and function in later life that do not include supplements 
and medical products, and may be easier adopted as a 
behavioural change in older adults.22
Milk for muscle health: current evidence and why this pilot is 
needed
Cow’s milk is an example of a whole food with the poten-
tial to ameliorate loss of skeletal muscle mass, strength 
and function. Whole milk (3.6% fat) is a source of 
high-quality proteins (whey and caseins), minerals (eg, 
calcium, phosphorus, magnesium), vitamins (eg, A, B, 
D and E), carbohydrates, bioactive lipids and fatty acids 
(monosaturated and polyunsaturated, and saturated fatty 
acids).23 Whey protein is considered superior to other 
protein sources for MPS after exercise in younger and 
older adults because of its greater bioavailability and solu-
bility, and higher content of the branched-chain amino 
acids, including leucine.24–26 Furthermore, the concur-
rent intake of milk fats with protein in whole milk has 
been shown to increase the use of EAA for MPS after 
exercise in young men compared with skimmed milk 
(0.3% fat),27 suggesting additional benefits of milk lipids 
for muscle. Other benefits of milk containing fat include 
reduction in exercise-related muscle damage, soreness 
and decline in muscle performance in young adults and 
athletes28 29 compared with energy-matched (isocaloric) 
carbohydrate drink. However, little is known about the 
effect of milk and protein-fat ratio in milk on muscle in 
older adults, particularly the impact on muscle function 
of varying milk fat contents (whole vs skimmed) providing 
>20 g protein/day after exercise.
We hypothesised that whole milk (3.6% fat), providing 
>20 g of protein and the same amount of energy as fat 
and protein-free carbohydrate drink, after structured 
exercise conducted in the community may be a feasible 
and acceptable intervention for maintaining skeletal 
muscle mass, strength and function in older adults at risk 
of sarcopenia.
Study aims
The primary aims are:
1. To examine the feasibility and acceptability of whole 
(3.6% fat) or skimmed milk (0.3% fat) in combination 
with RE as an intervention in community-dwelling old-
er adults aged ≥65 at risk of sarcopenia. This aim will 
answer the following questions: Is an intervention of 
2×500 mL milk+RE twice a week for 6 weeks (a) feasi-
ble and (b) acceptable to older adults?
2. To provide essential data for planned future substan-
tive research.
The secondary aim of the study will be to explore whether 
consumption of whole or skimmed milk+RE has an influ-
ence on physical performance, muscle mass, strength and 
self-reported QoL in older adults at risk of sarcopenia.
METhodS And AnAlySIS
Study design
This is a pilot study with a parallel-group design involving 
30 participants (aiming for 15 men and 15 women) aged 
≥65 years who will be randomised into three intervention 
groups: (group 1) ‘whole milk+RE’; (group 2) ‘skimmed 
milk+RE’ and (group 3) ‘control drink+RE’. Data will be 
collected from: (1) health and functioning assessments 
(screening, baseline and postintervention interview); (2) 
the nutrition+exercise intervention over 6 weeks and (3) 
participants’ feedback about the study.
Exclusion and inclusion criteria
The study will include older adults who are registered 
patients with general practitioner (GP) practices within 
the National Institute for Health Research (NIHR) North 
East and North Cumbria Clinical Research Network 
(CRN), UK. Table 1 lists the inclusion and exclusion 
criteria that are applied to patient database searches, 
performed in GP practices and screening interviews 
conducted by the research team.
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Table 1 Inclusion and exclusion criteria for the MIlkMAN: pilot
Criteria Patient database searches Screening interview
Inclusion
Aged 65 years and over
Live in the community
Exclusion
Diabetes mellitus type 1 or type 2 Lacks capacity to consent to participate
Chronic kidney disease stage 4 or 5 (estimated 
glomerular filtration rate<30 mL/min/1.73 m2)
Lactose intolerance
Liver function impairment (AST>2.5 times upper limit 
of normal range within the last 6 months)
Dislikes milk or cranberry juice (control drink)
Participated in a structured RE training and gym 
programme in the last month
Chronic lung disease requiring maintenance steroid 
therapy (eg, COPD, severe asthma)
Dislikes gym exercise with equipment
End-stage terminal illness Unintentional weight loss ≥5 kg in the last 3 months
Cardiac pacemaker or severe heart failure or other 
significant heart disease
Unable to understand instructions for muscle strength and 
function assessments in English or unwilling to participate 
in protocol when explained
Uncontrolled hypertension (>160/100 mm Hg) and 
uncontrolled hypotension (<100 mm Hg systolic) within 
last 6 months
An individual who the research team (exercise 
physiologist) evaluates as not suitable for the intervention 
because of safety reasons
Hip or knee replacement
Impaired mobility (unable to walk without an aid 
including wheelchair)
Current prescription of warfarin (potential interference 
with control drink)
BMI≥30 kg/m2
An individual who the GP feels it is inappropriate for 
the research team to approach for safety reasons: any 
medical and physical conditions that preclude safe 
participation in a RE programme (long-term conditions 
likely to lead impaired function over 6 months)
AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GP, general practitioner.
Study population and recruitment
Primary care recruitment will be carried out with the assis-
tance of North East and North Cumbria CRN, England, 
which provides support with access to general practices 
and their patients. Two practices in the North Tyneside 
Clinical Commissioning Group were identified for feasi-
bility using exclusion/inclusion criteria (table 1, left 
column) and provided feedback during the application 
for funding in 2018.
Recruitment will be organised in two stages: 
prescreening (GP practices) and screening (research 
team). At the prescreening stage, practices will identify 
potential participants from their patient database using 
exclusion/inclusion criteria (table 1, left column), and 
then mail out recruitment packs, containing detailed 
information about the study with a reply slip. Interested 
individuals will be interviewed over the telephone by a 
researcher using a 5-item SARC-F questionnaire (online 
supplementary appendix 1)30 to assess any difficulties 
with day-to-day activities (lifting and carrying 10 pounds, 
walking, rising from a chair and climbing stairs), and 
number of falls in the past year. Those evaluated by the 
research team to have no major difficulties that would 
preclude safe participation in the exercise programme 
(eg, unable to walk across a room), will be visited in their 
own home for a screening interview to obtain written 
informed consent, and to evaluate inclusion/exclusion 
criteria not screened through GPs (table 1, right column).
Those who meet the criteria will be assessed further for 
muscle strength (grip strength (GS) and function (walking 
speed) based on the following cut-offs: <20 kg (women) 
and<30 kg (men)31 for low GS; and <0.8 m/s or ≥5 s over 
4 m distance31 for low walking speed. GS measurements 
(high or low) at the screening interview will be used for 
minimisation along with sex to allow equal distribution of 
those with muscle strength weakness across the interven-
tion groups. However, the target number of those with 
‘low’ GS will not be established a priori. Therefore, the 
study will recruit older adults with some deficits in muscle 
health and those without for whom it is determined to 
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Table 2 Study outcome measures
Measure Screening Baseline Postintervention
Primary
  Feasibility and acceptability of intervention in a local gym setting ×
  Applicability ×
  Dosage and duration of intervention ×
  Compliance × ×
  Attrition × ×
  Adverse health effects ×
  Response rates to questionnaires, assessments and intervention × × ×
Secondary
  Short physical performance battery63 (balance, 4 m gait speed, 
5-chair stands)
× ×
  Muscle mass33 × ×
  Grip strengh32 × × ×
  SF-12 Health Survey34 × ×
  Barthel ndex35 × ×
SF-12, Short Form 12-item Health Survey.
be safe to participate in the study (primary aims), and 
hypothesised to benefit from the intervention regardless 
of the deficits (secondary aims).
Study outcomes
Table 2 lists the primary and secondary study outcomes 
and when they are completed.
The secondary outcome measures will explore differ-
ences in physical performance measures between the 
groups, preintervention and postintervention. GS (muscle 
strength)32 will be expressed as the maximum reading of 
six trials of both hands using a Jamar hand-held 5030J1 
dynamometer. Body composition (muscle mass) will be 
measured using Bioelectric Impedance Analysis33 (BIA; 
Tanita MC-780MA Body Composition Analyzer). Self-re-
ported QoL will be measured using 12-item Short Form 
Health Survey (SF-12),34 and activities of daily living with 
Barthel Index.35
Randomisation
A researcher will allocate 30 participants to one of the 
three interventions to ensure balanced allocation of 
participants between the groups based on sex and muscle 
strength (GS at screening assessment) using a free, 
open-source minimisation software (MiniPy 0.3, http:// 
minimpy. sourceforge. net).36 The software features 
elements of randomness in the minimisation algorithm 
by allocating the first participant randomly into one of 
the interventions, and assigning the subsequent partici-
pants on hypothetical stepwise allocation to every group 
and computation of the imbalance score corresponding 
to each allocation. The imbalance scores are compared 
and participants allocated to the group corresponding to 
the least imbalance score (preferred group).
The sample size for the pilot is not based on statis-
tical power but guided by the consideration to fulfil the 
primary aims of the study (eg, provide guidelines for the 
larger trial) and practical feasibility.37
Consent
Written informed consent will be obtained by a researcher 
visiting the participants during the home-based screening 
assessment prior to randomisation. Capacity to consent 
will be assessed using an established consent pathway. 
Throughout the active research phase (ie, from baseline to 
postintervention assessment), the notion of process consent 
will be implemented, requiring an ongoing exchange of 
information about the study and confirming the partici-
pants willingness to proceed, ensuring that participants are 
free to reconsider and withdraw from the study at any time. 
If a participant loses capacity during the research process, 
he/she will be withdrawn from the study.
Flow diagram of the study
A flow diagram of the study protocol with timelines is 
outlined in figure 1. The recruitment (assessment of eligi-
bility) up to allocation (randomisation into three groups) 
will be finalised within 3 months, followed by baseline 
assessments for health and functioning in participants’ 
homes, and a 6-week intervention in a local gym.
Home-based postintervention assessments, including 
participants’ feedback about the study, will be conducted 
the week following completion of the intervention, and 
finalised within 3 weeks. Data analysis will be completed 
after active data collection (from randomisation to 
postintervention assessment). Data collection for each 
participant will span approximately 10 weeks: (1) week 
1: consent and home-based screening assessment; (2) 
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Figure 1 Study flow chart. The recruitment (assessment of 
eligibility) up to allocation (randomisation into three groups) 
will be finalised within 3 months, followed by baseline 
assessments for health and functioning in participants’ 
homes, and a 6-week intervention in a local gym. A 
postintervention assessment will be conducted over 3 weeks 
in participants’ homes. Data will be analysed following data 
entry, cleaning and quality assurance over 2–3 months.
week 2: home-based baseline interview; (3) weeks 3–8: 
6-week intervention twice a week (12 visits at a local gym/
sport centre); (4) week 10: postintervention home-based 
interview. Except for the intervention (six consecutive 
weeks), this time scale can be adjusted to participants’ 
individual needs with a maximum 3 weeks gap between 
baseline assessment and the first week of intervention, 
and a maximum 3 weeks gap between the last week of 
intervention and postintervention assessment.
data collection
To determine the feasibility and acceptability of the study, 
the following data will be collected and analysed: the 
number of individuals approached; the reasons for not 
opting to take a part in the study (reported with permis-
sion); the recruitment and retention rates; the reasons 
for attrition; the completion of objective assessments and 
questionnaires; the number of RE sessions completed 
and compliance with the milk/control drink intake. 
Other health and functioning data will be collected at the 
home-based screening and baseline interview, during the 
intervention (at the gym), and at the home-based postin-
tervention interview. Participants’ attitudes and opinions 
about the study will be collected at the postintervention 
interview using a combination of multiple-response and 
standardised open-ended questions.
Screening interview
Once potential participants have been identified by the 
GP practices, having expressed an interest in participation 
and being interviewed over the phone by a researcher, a 
mutually convenient appointment will be arranged for a 
screening visit at the participant’s home. Participants will 
be screening for other exclusion/inclusion criteria not 
assessed at by the GP practices (table 1, right column), 
and to establish participants’ muscle strength (GS) and 
functioning status (walking speed) based on the estab-
lished cut-offs.31 Informed consent will be obtained before 
any assessment is undertaken. Eligible individuals will be 
informed about the study procedure and their journey 
through the study (from randomisation to postinterven-
tion assessment).
Baseline interview
Table 3 lists domains and assessments for the baseline 
interview with times needed to administer (in minutes). 
The detailed health and functioning profile will involve 
minimal risk and inconvenience to participants, and it 
will be conducted within 70 min (including breaks and 
excluding assessments performed at the gym).
Intervention
Resistance exercise
All participants will perform two RE sessions per week for 
6 weeks at a community leisure centre (The Parks, North 
Tyneside Council, North Shields, UK) that is easily acces-
sible and close to their residence. For each RE session a 
time slot of ~45–60 min in duration will be allocated, with 
a minimum of 48 hours between sessions. The sessions 
will be completed in groups of two to four participants 
under the supervision of an experienced exercise phys-
iologist (CH). Exercise intensity, volume, frequency and 
duration have been determined based on recent litera-
ture38–40 and the American College of Sports Medicine 
recommendations for older adults.39 With the exception 
of the structured exercise sessions and the nutritional 
intervention prescribed, participants will be asked to 
maintain their usual diet, level of physical activity and life-
style throughout the duration of the intervention period.
During the first RE session, participants will be familiar-
ised with the exercises (leg press, leg curl, seated row, chest 
press) as well as the equipment to be used throughout the 
intervention with correct technique demonstrated and 
extensively described. Following this, participants’ one 
repetition maximum (1RM) will be estimated for all four 
exercises using a previously established equation.41
Following the initial RE session, each remaining session 
will begin with a 5 min warm-up performed at progressive 
intensity using either a cycle ergometer or treadmill. Partic-
ipants will then complete 2–4 sets of 8–12 repetitions at a 
workload of 70%–79% 1RM38 39 for all four of the exercises 
listed above. Each session will conclude with a short cool-
down period of low-ntensity aerobic exercise, and (except 
the initial session) may be completed within 30 min.
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Table 3 Domains and assessments at baseline
Domain and assessment
Time to 
administer (min)
Sociodemographic profile Total: 6
  Age   
  Sex   
  Marital status   
  Education   
  Social class (NS-SEC)64   
  Deprivation (Multiple Index of Deprivation)65
General health Total: 54
  SF-12 Health Survey34 4
  Self-reported diseases diagnosed by 
a doctor
2
  List of medication (prescribed and 
over-the-counter)
2
  Mini Mental State Examination 10
  Geriatric Depression Scale (15-item 
version)66
7
  Barthel Index (activities of daily living)35 3
  Blood pressure (systolic and diastolic)* 5
  Intake24: 24 hours dietary recall67* 
(https://intake24.co.uk/)
20
  Appetite (a 4-item Simplified Nutritional 
Appetite Questionnaire)68*
1
Lifestyle Total: 5
  Self-reported physical activity69 3
  Smoking status 1
  Alcohol intake 1
Anthropometry Total: 14
  Demi-span 2
  Waist and hip circumference 3
  Calf circumference 2
  Muscle mass (body composition by 
BIA)33*
7
Physical functioning Total: 24
  Short Physical Performance Battery63 10
  Balance (a side-by-side tandem; semi-
tandem; tandem)
3
  4 m gait speed 3
  5-chair stands 4
  Maximum grip strength (measured 
three times in each arm)
4
NS-SEC, The National Statistics Socio-economic classification 
(Office for National Statistics, UK).
*Assessments done at the intervention site (gym) before and after 
each RE session (blood pressure), and before the first RE session 
(diet, appetite, body composition).
BIA, Bioelectric Impedance Analysis; RE, resistance exercise; SF-
12, 12-item Short Form Health Survey.
In an attempt to promote participants’ engagement 
with RE, each will receive a training log with diagrams 
and short instructions with space to record the details of 
the exercise completed. Participants’ gym attendance, 
sets and repetitions completed and weight lifted will 
be recorded following each RE session allowing for the 
calculation of measures of training load (eg, volume load 
(number of sets×number of repetitions×weight lifted)). 
In addition to measures of external training load, resis-
tance training intensity will be monitored using partic-
ipant ratings of perceived exertion. Using the CR100 
scale42 (online supplementary appendix 2), participants 
will provide an overall session rating of perceived exertion 
(sRPE) as well as differential ratings of perceived exertion 
for upper-body muscle exertion (RPE-U) and lower-body 
muscle exertion (RPE-L) approximately 10 min after the 
completion of each RE session.43 Each participant must 
complete at least 10 sessions (out of 12) to be considered 
compliant with the exercise programme.
Blood pressure and heart rate will be measured pre and 
post each RE session in each participant and compared 
with the guidelines provided by the American College of 
Cardiology/American Heart Association Task Force44 and 
existing literature.45 46 Muscle soreness will be assessed 
using a simple visual analogue scale (online supplemen-
tary appendix 3) at ~40–45 min and at ~6–7 hours after 
each RE session.
Nutritional intervention
On average, 500 mL milk contains ~20 g of protein 
needed to stimulate MPS above stimulation provided by 
RE.17 18 Whole cow milk (nutritional estimates of 22 UK 
samples during winter and summer) provides 66 kcal/100 
g of energy.47 Arla Cravendale whole milk contains 3.6 g 
fat, 3.4 g protein and 4.7 g of carbohydrates per 100 g 
of milk. Arla Cravendale skimmed milk contains 0.3 g 
fat, 3.6 g protein and 4.9 g of carbohydrate per 100 g of 
milk. The energy content of the control drink (cranberry 
juice; Ocean Spray Classic 23/kcal/100 g of energy) will 
be balanced to match whole milk energy content and 
supplemented with maltodextrin (4 kcal/g; www. mypro-
tein. com) on the day of intervention. Both milk and juice 
will be provided in packs of 1 L, bought fresh on a weekly 
basis through a local retailer and kept in a locked refrig-
erator at the Campus for Ageing and Vitality, Newcastle 
University.
The milk/control drink will be consumed as a bolus 
intake of 500 mL under the supervision of a researcher 
immediately after exercise during the recovery period, 
aiming for complete consumption within ~45 min prior 
to leaving the centre. The second dose of 500 mL will 
be consumed at the participants’ home over the next 4–5 
hours as a part of their usual diet with other foods. Partici-
pants’ compliance with consumption of the milk/control 
drink will be checked in the evening (~6–7 hours postex-
ercise). Each participant will be provided with a plastic 
measuring jug (500 mL) to measure their consumption 
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at home and to report it back to a researcher over the 
telephone.
Postintervention interview
Table 3 lists the domains and assessments that will be 
repeated at the postintervention interview. Briefly, a 
home visit will be arranged with each participant after the 
6-week intervention to assess his/her general health and 
physical functioning, including Short Physical Perfor-
mance Battery, muscle mass (body composition), muscle 
strength (GS), SF-12, Barthel Index, diet and appetite. 
Additionally, participants’ feedback will be collected at 
the end of the postintervention interview using a combi-
nation of structured multiple-response and standardised 
open-ended questions. The following themes will be 
explored: (1) attitudes and barriers to consuming of 
2×500 mL milk/control drink intake postexercise (eg, 
volume of liquid, taste, etc); (2) opinion about milk as 
a functional food for muscle strength/function; (3) 
changes in appetite and habitual diet because of milk/
control drink intake, and (4) what was liked and disliked 
about the study (intervention), including motivations 
and barriers to continue engagement in a local gym. The 
postintervention interview will be completed within 50 
min.
Statistical methods
As this is a feasibility and acceptability study aimed to 
inform a larger trial, the focus of data analysis will be 
descriptive. Using descriptive statistics (percentages, 
means (SDs)), we will calculate the response rates, the 
numbers consented and randomised, the retention rate 
and the number, length and frequency of interviews and 
RE sessions. Compliance with the milk and control drink 
intervention will be calculated as a percentage of actual 
consumption divided by expected consumption over the 
6-week intervention. Recording the number of repetitions 
for each exercise within each RE session and the weight 
lifted will allow calculation of several indices of training 
intensity. Mean and SDs (or equivalent) for questionnaire 
data and assessments will be reported at screening, base-
line and postintervention interview. Missing data will be 
recorded and evaluated.
Participants’ experiences and views about the study 
will be assessed with standardised open-ended questions. 
These data will be analysed using content analysis.48 
Content analysis is a flexible method for analysing text 
data. Coding categories will be derived directly from the 
data and themes will be identified supported with rele-
vant quotations of the participant’s perspectives.48
The sample size in this pilot study is limited to 30 partic-
ipants and therefore lacks statistical power for quantita-
tive analysis of the secondary outcomes.
dissemination, and patient and public involvement
A consumer panel was organised through the NIHR 
Research Design Service North East and North Cumbria, 
UK during the funding application phase of the study in 
September 2017 to obtain a Patient and Public Involve-
ment (PPI) in the study. We incorporated several panel's 
suggestions in the study design, including a clear iden-
tification of 'community-dwelling' older adults, and 
the intake of the second dose of milk/control drink 
within regular diet at home. The following key outputs 
will contribute to study dissemination and impact. The 
results of the study will be reported to the funder (NIHR 
Newcastle Biomedical Research Centre). The funder, 
sponsor and industry support (Arla) will have no role in 
the study design, conduct, data analysis, results interpreta-
tion or writing. The aim is that at least two peer-reviewed 
papers will be published in high-impact open-access jour-
nals, and the results will be presented at relevant scientific 
conferences. A lay summary of the main results will be 
presented to interested participants at a PPI event. A flyer 
featuring the main results of the study and, if desired, an 
individual report titled ‘My muscle function and strength 
before and after MIlkMAN’ will be prepared for all study 
participants. Reports with abnormal results (blood pres-
sure, body mass index (BMI), fat mass, Mini Mental State 
Examination and Geriatric Depression Scale) will be sent 
to general practices. Regular updates on the study prog-
ress will be reported on a publicly accessible website.
EThICS And dATA MonIToRIng And MAnAgEMEnT
Ethics
The study will be conducted in accordance with the prin-
ciples of the International Conference for Harmonisation 
of Good Clinical Practice (European Medicines Agency, 
2002). We have amended inclusion criteria for the study, 
and allowed the inclusion of individuals who have GS or 
walking speed above the European Working Group on 
Sarcopenia in Older People (EWGSOP 1) cut-offs.31
The study is funded by the National Institute for 
Health Research Newcastle Biomedical Research Centre, 
Newcastle University. Arla will provide milk and scientific 
support related to this nutritional intervention.
data monitoring
Throughout the study, the principal investigator (AG) will 
monitor recruitment, retention and compliance figures 
with the core research team (AG, CH, LD, TA). The core 
team will meet regularly to plan and evaluate study’s 
day-to-day activities. Monthly meetings will be organised 
with the co-investigators (KD, ES, AAS) to update on study 
management and progress. The core research team and 
co-investigators will prepare consents, assessments, study 
protocol and standard operating procedures for: (1) 
assessments and data reporting; (2) data management; 
(3) adverse events management and reporting, and (4) 
staff health risk assessment and safety procedures.
Adverse events
This is a low-risk study. There is a small chance of transient 
muscle soreness, gastrointestinal discomfort, metabolic 
changes and change in appetite. The chief investigator 
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(TA) is clinically trained to oversee the research process, 
and the research team is trained in health and safety 
procedures during data collection. Each participant will 
be closely monitored and asked about any adverse events 
occurring at home or in the gym. Any suspected adverse 
events will be reported to the chief investigator (TA), who 
will also offer clinical oversight of the study. Any serious 
adverse events, as evaluated by TA thought to be related 
to the intervention, will be reported immediately to the 
study sponsor and relevant ethics committee. Because of 
the low risk of adverse events, no independent Data Moni-
toring and Safety Committee will be appointed for this 
pilot study. The NHS indemnity insurance scheme will 
apply to cover the potential legal liability cover for harm 
to participants arising from the research. North Tyneside 
Council has the public and product liability cover for 
any potential harm arising from the fitness facility and 
equipment.
data management
Data will be collected and managed in accordance with 
the EU General Data Protection Regulation (2018). At 
consent, participants will be assigned a unique study 
ID that will be used to pseudonymise primary research 
data collected from interviews and intervention. Identifi-
able data will be stored separately and will be accessible 
only to members of the research team who have addi-
tional research passport checks approved as part of their 
research role. Pseudonymised paper-based assessments 
will be double data entered, and all study data will be 
stored on secure, fire-wall and password-protected servers 
of Newcastle University for 5 years.
data statement
Technical appendix, statistical code and dataset will be 
available from the AGE Research Group data manager.
dISCuSSIon
Strengths and limitations
To our knowledge, this is the first pilot study examining 
the fidelity of a whole food (milk) combined with RE 
intervention in community-dwelling older adults living in 
the UK. The primary aims of the MIlkMAN pilot are to 
determine the feasibility and acceptability of the interven-
tion in the community, and to provide essential data for 
planned future substantive research. The secondary aims 
are exploratory because the pilot lacks power to identify 
differences in physical functioning between the groups. 
However, the exploratory findings will be helpful in 
informing power calculations for the definitive study. The 
intervention will be conducted under the close super-
vision of a trained research team including an exercise 
physiologist and a health psychologist in a local gym with 
an easy access to older adults. Participants naïve to gym 
environment will benefit from the familiarisation with RE 
programme to encourage self-guided continued engage-
ment in the community. A postintervention interview 
in the pilot will include the collection of qualitative 
evidence on the barriers and motivators of communi-
ty-based interventions. To our knowledge, only one study 
has investigated the barriers and drivers of compliance 
with protein-rich diets with RE interventions,49 and none 
has included views of older adults about what motivates 
their willingness and keenness to continue.
This study has several limitations, which will inform the 
development of the subsequent trial. Physical activity and 
exercise are consistently reported as positive influences 
on muscle mass and function in healthy older adults,16 50 
while the evidence for positive effects of protein-rich foods 
above the effect of RE on muscle in older adults with 
adequate nutrition and activity levels has been more 
mixed.51 52 There may be more benefit for protein 
supplementation with RE in those with muscle weakness 
and physical frailty.20 As the MIlkMAN pilot will enrol 30 
participants with relatively healthy muscle, the effect of 
the intervention is likely to be minimal. To achieve clin-
ically meaningful differences between the groups and 
to examine the effect of milk above the effect of RE, a 
larger sample size, longer duration of the intervention 
and the inclusion of older adults with reduced physical 
functioning or probable sarcopenia4 will be necessary. 
Previous studies have reported difficulties in recruiting 
older adults with (probable) sarcopenia for various 
reasons, including the multifaceted nature of muscle 
health, the variety of muscle-related clinical outcomes 
relevant to sarcopenia and the lack of routine diagnosis 
of sarcopenia in clinical practice.53 However, the universal 
acceptance of a sarcopenia definition4 10 and cut-offs for 
sarcopenia components,4 10 the availability of sarcopenia 
screening tools30 for a rapid assessment of sarcopenia 
and wider use of GP surgeries (that routinely derive an 
electronic Frailty Index from data held in healthcare 
records54) for recruitment will increase the potential for 
enrolling appropriate participants to the larger trial. To 
reduce the risk of muscle injury, diabetes and exacerba-
tion of any other health risks not covered by the exclusion 
criteria, this pilot will not recruit older adults with BMI>30 
kg/m2. However, in the light of continued debate about 
the relationship between overweight/obesity and adverse 
health outcomes,55 and to maximise the recruitment, the 
substantive study will consider those with a BMI<35 kg/
m2.
We hypothesise that the ratio of protein to fat in whole 
milk in combination with RE may be beneficial to ageing 
muscle and superior to skimmed milk for MPS, phys-
ical performance and muscle soreness after exercise as 
observed in younger adults.27–29 To test this hypothesis 
and accurately quantify the differences across the groups 
in the future study, a validated chromatographic analysis 
of amino acid56 and fat content57 in Arla Cravendale milk 
will be necessary through the scientific support of Arla.
The present study will use BIA to assess body compo-
sition in participants preintervention and postinterven-
tion. Although BIA has been used widely to estimate 
lean body mass in community-dwelling older adults via 
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validated prediction formulas,58 there are several limita-
tions to the method, including low sensitivity to detect 
changes in muscle mass and the effect of hydration/dehy-
dration on the analysis.59 Ultrasound has been proposed 
as another non-invasive, safe and easy-to-use method suit-
able for longitudinal monitoring of muscle mass60 with 
higher sensitivity compared with BIA. While it requires 
technical skills,60 this method may be an appropriate 
strategy to minimise the limitations associated with BIA 
to detect changes in muscle mass. In addition, muscle 
measurements assessed by ultrasound can be compared 
with anthropometric measures used to estimate RE-in-
duced changes in muscle cross-sectional area, such as 
thigh circumference and a skinfold thickness,61 while 
keeping in mind the limitations of the method in older 
and obese adults.60
To minimise participant burden, the present study 
will use GS as a measure of overall muscle strength and 
for minimisation to allow equal distribution of partici-
pants with low GS across the groups. However, a future 
definitive trial will include repeat assessment of 1RM via 
submaximal testing at baseline and postintervention,62 to 
provide a more reliable and internally valid assessment of 
muscle strength. Repeat assessment of 1RM for all exer-
cises prescribed in the RE programme will enable a more 
specific evaluation of muscle strength changes following 
the intervention period.
In summary, this is the first pilot study examining the 
feasibility and acceptability of whole compared with 
skimmed milk in combination with RE conducted in a 
local gym in community-dwelling older adults in the UK. 
Qualitative data will be collected to inform the future 
substantive trial, and allow better understanding of the 
barriers and facilitators of community-based intervention. 
This pilot study has low statistical power to detect changes 
in physical functioning between the groups, however, the 
results will be used to aid the development and refine-
ment of a future clinical trial, including study design, 
power calculations, recruitment strategy, inclusion and 
exclusion criteria and outcome measures.
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